Trials / Completed
CompletedNCT02646904
Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Stefania La Grutta, MD · Academic / Other
- Sex
- All
- Age
- 6 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine in children with persistent AR the effect of the topically applied beclomethasone in comparison with cetirizine on nasal patency evaluated by acoustic rhinometry and subjective nasal symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nasal Beclomethasone Dipropionate | Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days. |
| DRUG | CERCHIO 10 mg/ml OS | For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days. |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-06-01
- Completion
- 2017-07-01
- First posted
- 2016-01-06
- Last updated
- 2017-11-20
Locations
2 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02646904. Inclusion in this directory is not an endorsement.